A thin film electroluminescence cell with the structure of ITO /PPV /PVK∶Eu（TTA）4C5H5NC16H33∶PBD /Alq 3 /Al has been fabricated.Red emissio n with a very sharp spectral band at 614nm was observed and a maximum luminance of 20cd·m -2 at 36V was obtained from the spin-coated device.The full width at half maximum of lu-minescent spectrum is less than 10nm.
Vanadium has well-documented lowering glucose properties both in vitro and in vivo. The design of new oxovanadium（IV） coordination compounds, intended for use as insulin-enhancing agents in the treatment of diabetes mellitus, can potentially benefit from a synergistic approach, in which the whole complex has more than an additive effect from its component parts. Biological testing with oxovanadium（IV） organic phosphonic acid, for insulin-enhancing potential included acute administration, by oral gavage in streptozotocin （STZ） diabetic rats. The complexes of oxovanadium（IV） amino acid-N-phosphonic acid exhibit higher lowering glucose activity in vivo. The interaction of the complexes of oxovanadium（IV） amino acid-N-phosphonic acid with DNA was investigated by agarose gel electrophoresis. The results indicated that these complexes have strong interaction with DNA.
Two guanidino acid oxovanadium(IV) complexes have been synthesized. Preliminary tests in vivo have shown that the two title complexes all display lowering glucose activity in vivo to STZ-rats. The effect of glucose-lowering of guanidino acetic acid oxovanadium(IV) complex in vivo is higher than that of guanidino propanoic acid oxovanadium(IV) complex.
